Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA

Tomaszuk‐Kazberuk, Anna; Kołtowski, Łukasz; Balsam, Paweł; Koziński, Marek; Kapłon‐Cieślicka, Agnieszka; Kupczyńska, Karolina; Domienik‐Karłowicz, Justyna; Budaj-Fidecka, Anna; Buszman, Piotr P.; Wybraniec, Maciej T.; Burchardt, Paweł; Michalski, Błażej; Jaguszewski, Miłosz

doi:10.5603/cj.2018.0080

Cited by 4 publications

(5 citation statements)

References 144 publications

(274 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The importance of reliable TR diagnosis is related to unfavorable impact of hemodynamically significant TR on prognosis, which results predominantly from its deleterious effects on RV dimensions and function. Other important clinical implications of significant TR include occurrence of rhythm disturbances such as atrial fibrillation and the need for chronic anticoagulation [27,28].…”

Section: Discussionmentioning

confidence: 99%

Echocardiographic assessment of tricuspid regurgitation and pericardial effusion after cardiac device implantation

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: The frequency of cardiac implantable electronic device (CIED) implantations is constantly increasing. Pericardial effusion (PE) and tricuspid regurgitation (TR) may occur after CIED implantation. The aim of the present study is to evaluate the prevalence and risk factors for new occurrences or progression of TR and PE early after CIED implantation. Methods: This is an ongoing , single-center, observational study of patients after their first CIED implantation, with an echocardiographic evaluation within 60 days before and 7 days after the procedure. Data are presented for first 110 consecutive patients who underwent CIED implantation from August 2015 to July 2016. Results: Median age was 75 years, and 44% were women. In total, 87 (79%) pacemakers, 21 (19%) implantable cardioverter-defibrillators and 2 cardiac resynchronization therapy devices were implanted. After CIED implantation, there was TR progression in 17 (16%) patients: 5 patients developed moderate TR, none developed severe TR. An increase in TR was more often observed after implantations performed by operators in training than by certified operators (35% vs. 12%, p = 0.02). New PE after the procedure was observed in 8 (7%) patients and was trivial (< 5 mm) in all cases. Patients with new PE after implantation had lower baseline hemoglobin levels and tended to be women. Conclusions: New PE and an increase in TR severity are rare complications early after CIED implantation. Operator experience might be related to TR progression. Increasing the number of patients in the current ongoing study will allow a more reliable assessment of the prevalence and risk factors of these complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Echocardiographic assessment of tricuspid regurgitation and pericardial effusion after cardiac device implantation

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…The minimum period between successive kidney function assessments in months may be calculated by dividing CrCl by 10. In patients with co-existing risk factors (e.g., older age, frailty, and multiple comorbidities), more frequent monitoring is suggested [8][9][10].…”

Section: Anticoagulation In Non-covid-19 Patients and In Quarantined Asymptomatic Or Mildly Symptomatic Non-hospitalized Individualsmentioning

confidence: 99%

Pharmacotherapy of atrial fibrillation in COVID-19 patients

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The present study focused on different forms of anticoagulation in a specific group of patients with CKD, due to their universal usage and accumulation risk in impaired renal function [9], usage referring to: heparins, fondaparinux, rivaroxaban, apixaban, edoxaban, dabigatran. Of note, only elimination of unfractionated heparin is independent of renal function.…”

Section: A Different Form Of Anticoagulationmentioning

confidence: 99%

“…The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with preserved renal function anticoagulated with non-vitamin K antagonist oral anticoagulants due to AF recommends monitoring renal function at least once a year in order to detect deterioration of renal function and for adaptation of dosage [9]. In patients with eGFR < 60 mL/min/1.73 m 2 they recommended evaluation of renal function more frequently [30].…”

Section: A Different Form Of Anticoagulationmentioning

confidence: 99%

The use of anticoagulants in chronic kidney disease: Common point of view of cardiologists and nephrologists

Domienik‐Karłowicz¹,

Tronina

Lisik³

et al. 2020

Cardiol J.

Self Cite

View full text Add to dashboard Cite

In patients diagnosed with chronic kidney disease (CKD), atrial fibrillation (AF) is associated with an increased risk of thromboembolism and stroke. Moreover, patients with CKD-especially those in end-stage renal disease-also present an increased risk of bleeding. Oral anticoagulation is the most effective form of thromboprophylaxis in patients with AF and an increased risk of stroke. However, the underuse of these drugs was observed, mainly due to safety reasons and restricted evidence on efficacy. Much evidence suggests that non-vitamin K-dependent oral anticoagulant agents significantly reduce the risk of stroke, intracranial hemorrhage, and mortality, with lower to similar major bleeding rates compared with vitamin K antagonists, such as warfarin, in normal renal function subjects. Thus, they are currently recommended for that group of patients. However, their metabolism is largely dependent on the kidneys for elimination, and current knowledge in this area is limited due to patients with a decreased glomerular filtration rate are usually excluded from clinical trials. The present review article focuses on currently available data on oral anticoagulants in patients with moderate to advanced chronic kidney disease and those with end stage renal disease.

show abstract

Use of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation — Messages from the 2018 EHRA

Abstract: Strict adherence plays a key role NOAC's anticoagulant effect diminishes after 12-24 hours which makes strict adherence to drug intake a critical issue [28]. Importantly, NOAC plasma concentrations and general coagulation tests 424 www.cardiologyjournal.org

Cited by 4 publications

References 144 publications

Echocardiographic assessment of tricuspid regurgitation and pericardial effusion after cardiac device implantation

Echocardiographic assessment of tricuspid regurgitation and pericardial effusion after cardiac device implantation

Pharmacotherapy of atrial fibrillation in COVID-19 patients

The use of anticoagulants in chronic kidney disease: Common point of view of cardiologists and nephrologists

Contact Info

Product

Resources

About